This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy ...

Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon ...

They are due to leave by the end of this year to set up an as-yet unnamed "independent biotechnology company to research and ...

Immutep's ASX-listed stock fell more than 88% on the news that its phase 3 trial TACTI-004 of LAG-3 inhibitor eftilagimod alfa (efti) as a first-line treatment for non-small cell lung cancer (NSCLC) ...

Whilst most of those working in the pharmaceutical industry have felt the pressures of rising costs and thinning pipelines over the last twenty years, some entrepreneurial souls have managed to turn a ...

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

In any clinical context, continuity of care is an important contributor to long-term outcomes. Treating serious mental ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

The US regulator has not, however, cleared leucovorin for autism spectrum disorder (ASD) itself, stepping back from the furore that broke out last year when President Trump claimed it could be a ...